Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Recombinant Anti-tumor and Anti-Virus Protein for Injection Plus Capatabine in Treating Patients With Metastatic Colorectal Cancer After Failure of Standard Treatment

NCT02068131 is registered in ClinicalTrials.gov with The Affiliated Hospital of the Chinese Academy of Military Medical Sciences as lead sponsor.

NCT NCT02068131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02068131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Recombinant Anti-tumor and Anti-Virus Protein for Injection Plus Capatabine in Treating Patients With Metastatic Colorectal Cancer After Failure of Standard Treatment
Lead sponsor
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 2014
Completion date
December 31, 2016
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer